Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HCA Healthcare, Inc. (NYSE: HCA) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. HCA Healthcare is a Nashville-based provider of healthcare services with 191 hospitals and approximately 2,500 ambulatory sites of care, and its filings offer detail on how it finances and governs this network, as well as how it reports operating results to shareholders.
For this issuer, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for information on the performance of its general medical and surgical hospitals and related ambulatory facilities. These filings typically include discussions of segment operations, risk factors relevant to healthcare services, and descriptions of the company’s learning health system approach. On Stock Titan, AI-powered summaries can help explain key sections of lengthy 10-K and 10-Q documents in more accessible language.
HCA Healthcare also uses Form 8-K to report material events. Recent 8-Ks have described items such as the public offering of senior notes by HCA Inc., the company’s direct, wholly owned subsidiary, including the terms of the notes, related indentures and covenants, and the planned redemption of existing senior notes. Other 8-K filings have announced quarterly results, cash dividend declarations on HCA common stock, and changes in the Board of Directors.
Debt investors may focus on filings that describe senior notes, indentures and guarantees, including covenants that limit liens, sale and lease-back transactions, or major corporate reorganizations. Equity investors may review proxy materials and compensation disclosures, along with periodic reports, to understand governance structures and board committee responsibilities, such as the Audit and Compliance Committee and the Patient Safety and Quality of Care Committee.
Through Stock Titan, users can view real-time updates from EDGAR, see insider-related forms such as Form 4 when available, and rely on AI-generated highlights to quickly identify notable changes, obligations and events in HCA Healthcare’s SEC reporting history.
HCA Healthcare CEO Samuel N. Hazen reported equity transactions in company common stock. On February 10, 2026, he acquired 54,934 shares at $0 per share as a grant tied to performance share units that fully vested at 200% of the original award.
On the same date, 21,323 shares were disposed of at $502.05 per share to satisfy tax withholding obligations, leaving 64,842 shares held directly. He also reports indirect ownership, including 200,000 shares held by a 2025 GRAT and 813,320 shares held by an LP.
HCA Healthcare EVP and COO Jon M. Foster reported equity award activity. On February 10, 2026, he acquired 15,696 shares of common stock at $0 per share as a grant. On the same date, 5,888 shares were withheld at $502.05 per share to cover tax obligations, leaving 23,062 directly held shares.
The award relates to 7,848 performance share units granted on January 30, 2023, which could vest from zero to twice the original grant based on cumulative earnings per share for fiscal years 2023–2025. Based on the company’s earnings performance, 200% of the units vested, resulting in the reported share delivery.
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported equity award activity in company stock. On February 10, 2026, he acquired 9,628 shares of common stock at $0 per share through a grant or award, increasing his direct holdings to 35,580.9017 shares.
On the same date, 3,501 shares were disposed of at $502.05 per share to satisfy tax withholding obligations, leaving him with 32,079.9017 directly owned shares. These shares relate to 4,814 performance share units granted on January 30, 2023 that vested at 200% of the original grant based on 2023–2025 earnings per share performance.
HCA Healthcare SVP & Chief Human Resources Officer Jennifer Berres reported multiple stock transactions. On February 10, 2026, she acquired 7,116 shares of common stock at $0 from previously granted performance share units that vested at 200% of the original 3,558-unit award after HCA met its 2023–2025 earnings per share goals. The same day, 2,515 shares were withheld at $502.05 per share to cover tax obligations. On February 11, 2026, she sold 4,010 shares at $503 per share and another 4,010 shares at a weighted average price of $526.1646, leaving her with 11,993 directly owned shares.
A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9. The planned sale is through Merrill Lynch on the NYSE, with an approximate sale date of 02/11/2026.
The shares to be sold were acquired via vesting of stock awards from HCA Healthcare, Inc. on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment. The notice also states that the seller represents they do not know any undisclosed material adverse information about HCA’s operations.
HCA Healthcare insider Thomas F. Frist Jr. reported an internal reorganization of his indirect holdings. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA shares for 36,557,141 newly issued shares from HCA in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
After the exchange, Frisco Holding II holds 36,557,141 HCA shares, and Hercules Holding II holds 32,282,889 shares. Frist may be deemed to have voting and investment control over these entities but disclaims beneficial ownership except for his pecuniary interests, which are tied to specified partnership units and trusts.
HCA Healthcare director and 10% owner William R. Frist reported complex internal equity moves involving investment entities tied to his family. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA shares for 36,557,141 newly issued shares from HCA in a tax-related reorganization treated as a partnership conversion and Section 368(a) reorganization.
After the transactions, Frisco Holding II holds 36,557,141 HCA shares and Hercules Holding II holds 32,282,889 shares, with additional indirect holdings through trusts, family partnerships, and family members. Frist may be deemed to have voting and investment control over these entities but formally disclaims beneficial ownership beyond his economic interests. His direct holding of 12,931 shares includes restricted share units payable in 12,875 shares when he leaves the board.
HCA Healthcare director and 10% owner Thomas F. Frist III reported an internal share reorganization involving entities linked to him. On February 6, 2026, Frisco Holding II disposed of 36,629,188 HCA common shares in exchange for 36,557,141 newly issued shares from HCA in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
Frisco Holding II now holds 36,557,141 shares for a private investor group that includes affiliates of HCA founder Dr. Thomas F. Frist Jr. Frist III may be deemed to have voting and investment control but disclaims beneficial ownership beyond his economic interest through partnership units and related trusts. Separately, Hercules Holding II holds 32,282,889 HCA shares for a similar investor group, with Frist III likewise only recognizing his pecuniary interest. He also directly holds 14,817 restricted share units that will settle in HCA shares when he ceases to be a director.
HCA Healthcare insider-related entities completed a large internal share reorganization. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA common shares for 36,557,141 newly issued shares in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
After these transactions, Frisco Holding II holds 36,557,141 HCA shares, and Hercules Holding II holds 32,282,889 shares, with additional smaller indirect holdings through joint, spouse, and children’s trusts. The reporting person may be deemed to have voting and investment control through these entities but disclaims beneficial ownership beyond her pecuniary interests.
HCA Healthcare’s Form 4 shows that major shareholder Hercules Holding II, a 10% owner, made a large internal share distribution. On February 6, 2026, Hercules Holding II distributed 36,629,188 shares of HCA common stock for no consideration, on a pro rata basis, to Frisco Holding II. After this non-cash, reallocation-type transaction, Hercules Holding II directly held 32,282,889 HCA shares. The filing notes that Hercules Holding II is held by a private investor group that includes affiliates of HCA founder Dr. Thomas F. Frist Jr., highlighting that this is a movement of shares within an affiliated investor structure rather than an open-market sale.